Financials
| 3rd Quarter Results | Oct. 29, 2025 |
| 2nd Quarter Results | Jul. 30, 2025 |
| 1st Quarter Results | Apr. 30, 2025 |
| GSK plc 2024 Annual Report on Form 20-F | Mar. 03, 2025 |
| GSK publishes Annual Report 2024 | Feb. 27, 2025 |
| 2024 Annual Financial Report | Feb. 27, 2025 |
| Final Results | Feb. 05, 2025 |
Proxies
| Result of AGM | May. 07, 2025 |
| GSK Proxy Form 2025 | Mar. 24, 2025 |
| GSK AGM Notice 2025 | Mar. 24, 2025 |
| Notice of AGM | Mar. 24, 2025 |
| Result of AGM | May. 08, 2024 |
| GSK Proxy Form 2024 | Mar. 25, 2024 |
| GSK AGM Notice 2024 | Mar. 25, 2024 |
Ownership Update
| Transaction in Own Shares | Oct. 31, 2025 |
| Director/PDMR Shareholding | Oct. 30, 2025 |
| Transaction in Own Shares | Oct. 30, 2025 |
| Transaction in Own Shares | Oct. 29, 2025 |
| Transaction in Own Shares | Oct. 28, 2025 |
| Transaction in Own Shares | Oct. 27, 2025 |
| Transaction in Own Shares | Oct. 24, 2025 |
Announcements
| GSK ADC gets orphan drug designation in the EU | Oct. 28, 2025 |
| Blenrep approved by US FDA in multiple myeloma | Oct. 24, 2025 |
| Positive data for low carbon version Ventolin MDI | Oct. 22, 2025 |
| Latozinemab data read out | Oct. 22, 2025 |
| Positive CHMP Opinion for GSK on Shingrix PFS | Oct. 21, 2025 |
| GSK share positive Ph3 data on tebipenem HBr | Oct. 21, 2025 |
| GSK receives expanded Shingrix approval in China | Oct. 14, 2025 |
Prospectuses
| GSK plc;GLAXOSMITHKLINE CAPITAL PLC;GSK Capital B.V.;GSK Capital K.K - Base prospectus (debt) | Sep. 07, 2022 |